Anti-Botulinum neurotoxin type A [CR1]

Absolute Antibody

Anti-Botulinum neurotoxin type A [CR1]

7

CR1 binds to both BoNT/A1 and BoNT/A2 with high affinity (CR1 scfv: KD BoNT/A1 ~ 0.13 nM; KD BoNT/A2 ~ 0.4 nM. CR1 IgG: KD BoNT/A1 ~ 2.5 pM; KD BoNT/A2 ~ 1.7 nM.). CR1 Fab fragment binds to the BoNT/A1 binding domain, at the interface between the N-termin

Antibody binding can be studied by FC and the antibody also shows in vivo neutralizing activity against botulinum neurotoxin - the neutralizing activity is increased when administered in combination with the human BoNT/A antibodies RAZ1 and 2G11.

Flow Cytometry, Neutralisation/Blocking

Neutralize; FC

Research Use Only

Monoclonal

CR1

bont

botulinum neurotoxin type A

botulinum neurotoxin type A; CBO_RS04150; CBO0806

Human

Botulinum neurotoxin type A

This reformatted human antibody was made using the variable domain sequences of the original Human IgG1 format, for improved compatibility with existing reagents, assays and techniques.

Bacteria

Clostridium

CR1 was produced by a yeast gene diversity library used to increase the affinitiy of scFv AR2 for BoNT/A2, while maintinaing high affinity binding to BoNT/A2. AR2 was generated after multiple rounds of affinity maturation of the humanized C25, which itself was created by CDR-grafting from the parental murine C25. Murine C25 was prepared by constructing a scFv phage display library from mice immunized with recombinant BoNT/A binding domain (Hc).

-20°C,2°C to 8°C

12352203